Marker Therapeutics (NASDAQ:MRKR) Shares Break Above 200 Day Moving Average – What’s Next?

Marker Therapeutics, Inc. (NASDAQ:MRKR – Get Free Report)’s stock price crossed above its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $1.31 and traded as high as $1.68. Marker Therapeutics shares last traded at $1.32, with a volume of 35,846,329 shares traded.

Key Marker Therapeutics News

These are some of the MRKR news items that stood out recently:

  • Positive Sentiment: HC Wainwright raised its earnings-per-share estimates across several quarters and fiscal years, including narrowing its projected losses for FY2026–FY2030. The firm maintained a Buy rating. HC Wainwright estimate revisions
  • Neutral Sentiment: An earlier report said MRKR had crossed above its 200-day moving average, a potentially favorable technical signal, though it may not explain the more recent weakness. Marker Therapeutics stock crosses above 200-day moving average
  • Negative Sentiment: HC Wainwright’s forecasts still project losses in the coming years. Separately, the company’s latest reported quarter showed revenue of $1.29 million, below the $2.12 million consensus estimate, even though its loss per share was narrower than expected.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on MRKR shares. Weiss Ratings cut shares of Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, November 13th. HC Wainwright reaffirmed a “buy” rating on shares of Marker Therapeutics in a report on Friday, August 21st. Finally, Zacks Research cut Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 13th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $10.00.

Read Our Latest Report on Marker Therapeutics

Marker Therapeutics Price Performance

The business has a 50 day moving average of $1.03 and a 200 day moving average of $1.30. The company has a market cap of $18.17 million, a PE ratio of -2.79 and a beta of 1.65.

Marker Therapeutics (NASDAQ:MRKR – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. The firm had revenue of $1.29 million for the quarter, compared to analysts’ expectations of $2.12 million. Sell-side analysts forecast that Marker Therapeutics, Inc. will post -0.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Marker Therapeutics stock. Concurrent Investment Advisors LLC bought a new position in Marker Therapeutics, Inc. (NASDAQ:MRKR – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 67,963 shares of the company’s stock, valued at approximately $100,000. Concurrent Investment Advisors LLC owned approximately 0.41% of Marker Therapeutics at the end of the most recent quarter. 22.39% of the stock is owned by institutional investors.

About Marker Therapeutics

(Get Free Report)

Marker Therapeutics is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. Its platform aims to produce T cells that recognize multiple tumor-associated antigens, with the goal of helping them target cancer cells while reducing the risk that tumors evade treatment by losing a single antigen. The company’s pipeline includes multi-antigen-specific T-cell candidates for blood cancers. Its programs have included MT-601, studied for lymphoma, and MT-401, developed for acute myeloid leukemia and other hematologic malignancies.

Further Reading

Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.